Bonesupport Holding AB (publ)

Stockholm Stock Exchange BONEX.ST

Bonesupport Holding AB (publ) Gross Profit for the year ending December 31, 2023: USD 53.39 M

Bonesupport Holding AB (publ) Gross Profit is USD 53.39 M for the year ending December 31, 2023, a 87.78% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Bonesupport Holding AB (publ) Gross Profit for the year ending December 31, 2022 was USD 28.43 M, a 36.12% change year over year.
Bonesupport Holding AB (publ) Gross Profit for the year ending December 31, 2021 was USD 20.89 M, a 6.64% change year over year.
Bonesupport Holding AB (publ) Gross Profit for the year ending December 31, 2020 was USD 19.59 M, a 35.48% change year over year.
Bonesupport Holding AB (publ) Gross Profit for the year ending December 31, 2019 was USD 14.46 M, a 57.74% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Stockholm Stock Exchange: BONEX.ST

Bonesupport Holding AB (publ)

CEO	Mr. Emil Billbäck
IPO Date	June 21, 2017
Location	Sweden
Headquarters	Scheelevägen 19
Employees	131
Sector	Materials
Industries Plastics 3D Printing Biotechnology Cement Ceramics Composite Materials Construction Materials Containers & Packaging Glass

Description

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable, moldable, and drillable synthetic bone void filler that includes hydroxyapatite, calcium sulfate, and the radio-contrast agent iohexol; CERAMENT G, a gentamicin injectable ceramic bone graft substitute; and CERAMENT V, a vancomycin injectable synthetic bone void filler. It also develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, revision artroplasty, and oncology, as well as bone and foot infections due to diabetes. The company was founded in 1999 and is headquartered in Lund, Sweden.

Key trends

Past 5 years